CD59 Antibody [193-27] | 33-508

CD59 Antibody [193-27] | 33-508 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Stimulated human leukocytes were used as the immunogen for the CD59 antibody.

Research Area: Immunology

Tested Application: Func, Flow, IF

Application: Functional Activity (Order SAF formulation)
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Optimal dilution of the CD59 antibody should be determined by the researcher.

Specificiy: Does not react with Baboon, Horse

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: PEG precipitation

Clonality: Monoclonal

Clone: 193-27

Isotype: IgM, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: CD59 Antibody: 1F5, EJ16, EJ30, EL32, G344, MIN1, MIN2, MIN3, MIRL, HRF20, MACIF, MEM43, MIC11, MSK21, 16.3A5, HRF-20, MAC-IP, p18-20, CD59 glycoprotein, 1F5 antigen

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Reacts with human CD59, a 20kDa glycosyl phosphatidyl-inositol (GPI) -anchored cell surface protein (Workshop VI; Code N-L036) . CD59 regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. CD59 is widely distributed on cells in all tissues. It inhibits formation of MAC, thus protecting cells from complement-mediated lysis. The expression of CD59 on erythrocytes is important for their survival. Genetic defects in GPI-anchor attachment, that cause a reduction or loss of CD59 and CD55 on erythrocytes produce the symptoms of the disease paroxysmal hemoglobinuria (PNH) . This mAb recognizes CD59 transfected cells. It is useful for study on GPI-anchored proteins, PNH and CD59 functions.